Continuing its strategy of investing in early-stage start-ups as part of its Sunrise Initiative, Sanofi has entered into a 5-year collaboration with Stanford University spin-out DiCE Molecules to discover potential new oral therapies for up to 12 targets spanning disease areas of strategic interest to Sanofi. DiCE’s small molecule discovery platform has the potential to develop compounds that act by unlocking protein-protein interfaces, which have historically been regarded as intractable targets for orally bioavailable drugs. Sanofi will provide funding of more than US$50 M to DiCE plus up to US$184 M in milestone payments per target.